Funding for this research was provided by:
Narodowe Centrum Nauki (2014/14/E/NZ6/00182, 2015/18/M/NZ6/00334)
Text and Data Mining valid from 2019-02-06
Received: 6 July 2018
Accepted: 17 January 2019
First Online: 6 February 2019
Compliance with ethical standards
: Anna Felberg, Aleksandra Urban and Marcin Okrój are named as inventors in patent application: World Intellectual Property Organization (WIPO) ST 10/C PL425133 “Point mutations in complement C2 protein and complement factor B enhancing the cytotoxic activity of antitumour antibodies, their pharmaceutical composition and application”. The other authors declare that they have no conflict of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the Local Bioethical Committee at Medical University of Gdańsk and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The Local Bioethical Committee at Medical University of Gdańsk granted ethical approval for this study (Approval number: Agreement no. NKBBN/500/2016).
: Written informed consent was obtained from all individual participants included in the study. Every participant was provided with an information sheet and consent form to be signed both by the participant and the person taking consent.
: Ramos, Daudi, SU-DHL-8 and WSU-NHL cells were obtained from German Collection of Microorganisms and Cell Cultures. Namalwa and BJAB cells were obtained from the American Type Culture Collection. All cell lines were aliquoted and cryopreserved after the first few passages. Cells used for experiments were grown from such stock aliquots, routinely checked for Mycoplasma infection when cultured and never kept in continuous culture for more than ten passages.